A small-molecule probe for hepatitis C virus replication that blocks protein folding

Area of Science:

• Virology
• Molecular Biology
• Drug Discovery

Background:

• Hepatitis C virus (HCV) poses a significant global health challenge.
• Understanding host-viral interactions is crucial for developing novel antiviral therapies.
• Small molecules can be valuable tools for studying viral pathogenesis.

Purpose of the Study:

• To identify small molecules that inhibit HCV replication.
• To explore the potential of abscisic acid (ABA) analogs as antiviral agents.
• To investigate the mechanism of action for identified compounds.

Main Methods:

• A cell-based screen using subgenomic HCV replicons was employed.
• 18 different abscisic acid (ABA) analogs were tested for antiviral activity.
• Promising compounds, including origamicin, underwent further mechanistic studies.

Main Results:

• 18 ABA analogs demonstrated the ability to inhibit HCV replication.
• Origamicin exhibited antiviral activity by inhibiting host proteins essential for protein folding.
• This suggests ABA-derived scaffolds can target mammalian protein folding pathways.

Conclusions:

• Abscisic acid analogs represent a novel class of compounds with potential for HCV therapy.
• Origamicin serves as a valuable tool for investigating host and viral protein maturation.
• The study highlights the therapeutic potential of targeting host protein folding mechanisms in viral infections.